New drug approval by FDA for MDS related anemia
On April 3, 2020, the Food and Drug Administration approved luspatercept-aamt (REBLOZYL) for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell (RBC) units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
The main efficacy was reported as the absence of any RBC transfusion during any consecutive 8-week period between Weeks 1 and 24.
Reblozyl was given once every 3 weeks by subcutaneous injection.
Amanullah Khan, MD, PhD.
President, Cancer Center Associates